Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 51w89
2. Cisatracurium
3. Cisatracurium Besilate
4. Nimbex
1. 96946-42-8
2. Nimbex
3. Cisatracurium Besilate
4. Cisatracurium (besylate)
5. 51w89
6. Cisatracurium Besylate [usan]
7. Cisatracurium (as Besilate)
8. 80ys8o1mbs
9. Cisatracurium Besilate [inn]
10. Chebi:3721
11. (1r,1'r,2r,2'r)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) Benzenesulfonate
12. 96946-42-8 (besylate)
13. (1r,2r)-2-(2-carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium Benzenesulfonate, Pentamethylene Ester
14. (1r-cis,1'r-cis)-atracurium Besylate
15. 51-w89
16. 51w-89
17. 51-w-89
18. Cisatracurium Besilate (inn)
19. Nimbex Preservative Free
20. Cis-atracurium Besylate
21. Unii-80ys8o1mbs
22. Nimbium
23. Atracurium Besylate 1r-cis,1r'-cis Form
24. Nimbex Forte
25. Ncgc00017127-01
26. Cas-64228-81-5
27. Nimbex (tn)
28. Cisatracurium Besylate Preservative Free
29. Cis-atracurium Besilate
30. Isoquinolinium,2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-,(1r,1'r,2r,2'r)-, Dibenzenesulfonate
31. Y78ps7mede
32. Schembl40669
33. Cisatracurium Besylate (usp)
34. Cisatracurium Dibenzenesulfonate
35. Cisatracurium Besylate (nimbex)
36. Chembl1200641
37. Cisatracurium Besylate (~90%)
38. Dtxsid10895045
39. Hms3715p04
40. Hms3884l07
41. Cisatracurium Besylate [mi]
42. Benzenesulfonate;5-[3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoate
43. Ex-a2646
44. Mfcd00871018
45. S2113
46. Cisatracurium Besylate [vandf]
47. Akos026750111
48. Cisatracurium Besilate [mart.]
49. Ccg-221271
50. Cisatracurium Besilate [who-dd]
51. Cisatracurium Besylate [usp-rs]
52. (1r,2r,1'r,2'r)-atracurium Besylate
53. Bs-17985
54. Hy-13596
55. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, Dibenzenesulfonate, (1r-(1alpha,2alpha(1'r(sup *),2'r(sup *))))-
56. Cisatracurium Besylate [orange Book]
57. Cisatracurium Besilate [ep Monograph]
58. Sw222230-1
59. Cisatracurium Besylate [usp Monograph]
60. 51 W89
61. D00759
62. Q267669
63. W-60404
64. Z2216208615
65. Atracurium Besylate, (1r,1'r,2r,2'r)-(+/-)-
66. Cisatracurium Besilate, Europepharmacopoeia (ep) Reference Standard
67. Cisatracurium Besylate, United States Pharmacopeia (usp) Reference Standard
68. Cisatracurium For Peak Identification, Europepharmacopoeia (ep) Reference Standard
69. Cisatracurium For System Suitability, Europepharmacopoeia (ep) Reference Standard
70. (1r,1'r,2r,2'r)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium)benzenesulfonate
71. (1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-2-(3-{[5-({3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propanoyl}oxy)pentyl]oxy}-3-oxopropyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium Dibenzenesulfonate
72. (1r,2r,1'r,2'r)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] Bisbenzenesulfonate
73. (1r-cis,1'r-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] Bisbenzenesulfonate
74. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1r,1'r,2r,2'r)-, Benzenesulfonate (1:2)
75. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1r,1'r,2r,2'r)-, Dibenzenesulfonate
76. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1r,1'r,2r,2'r)-rel, Dibenzenesulfonate
77. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, Dibenzenesulfonate, (1r-(1.alpha.,2.alpha.(1'r*,2'r*)))-
78. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, Dibenzenesulphonate, (1r-(1.alpha.,2.alpha.(1'r*,2'r*)))-
| Molecular Weight | 1243.5 g/mol |
|---|---|
| Molecular Formula | C65H82N2O18S2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 18 |
| Rotatable Bond Count | 26 |
| Exact Mass | 1242.50040612 g/mol |
| Monoisotopic Mass | 1242.50040612 g/mol |
| Topological Polar Surface Area | 258 Ų |
| Heavy Atom Count | 87 |
| Formal Charge | 0 |
| Complexity | 1560 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 6 | |
|---|---|
| Drug Name | Cisatracurium besylate |
| Active Ingredient | Cisatracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2mg base/ml |
| Market Status | Prescription |
| Company | Sandoz |
| 2 of 6 | |
|---|---|
| Drug Name | Nimbex |
| Drug Label | NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is one of 10... |
| Active Ingredient | Cisatracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2mg base/ml |
| Market Status | Prescription |
| Company | Abbvie |
| 3 of 6 | |
|---|---|
| Drug Name | Nimbex preservative free |
| Drug Label | Cisatracurium besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is one of 10isomers... |
| Active Ingredient | Cisatracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2mg base/ml; eq 10mg base/ml |
| Market Status | Prescription |
| Company | Abbvie |
| 4 of 6 | |
|---|---|
| Drug Name | Cisatracurium besylate |
| Active Ingredient | Cisatracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2mg base/ml |
| Market Status | Prescription |
| Company | Sandoz |
| 5 of 6 | |
|---|---|
| Drug Name | Nimbex |
| Drug Label | NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is one of 10... |
| Active Ingredient | Cisatracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2mg base/ml |
| Market Status | Prescription |
| Company | Abbvie |
| 6 of 6 | |
|---|---|
| Drug Name | Nimbex preservative free |
| Drug Label | Cisatracurium besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is one of 10isomers... |
| Active Ingredient | Cisatracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2mg base/ml; eq 10mg base/ml |
| Market Status | Prescription |
| Company | Abbvie |
Neuromuscular Blocking Agents
Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). Both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc. (See all compounds classified as Neuromuscular Blocking Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - EQ 10MG BASE/...DOSAGE - INJECTABLE;INJECTION - EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20551
DOSAGE - INJECTABLE;INJECTION - EQ 2MG BASE/M...DOSAGE - INJECTABLE;INJECTION - EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20551
Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Topical
Solubilizers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
77
PharmaCompass offers a list of Cisatracurium Besylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cisatracurium Besylate manufacturer or Cisatracurium Besylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cisatracurium Besylate manufacturer or Cisatracurium Besylate supplier.
PharmaCompass also assists you with knowing the Cisatracurium Besylate API Price utilized in the formulation of products. Cisatracurium Besylate API Price is not always fixed or binding as the Cisatracurium Besylate Price is obtained through a variety of data sources. The Cisatracurium Besylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cisatracurium Besylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cisatracurium Besylate, including repackagers and relabelers. The FDA regulates Cisatracurium Besylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cisatracurium Besylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cisatracurium Besylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cisatracurium Besylate supplier is an individual or a company that provides Cisatracurium Besylate active pharmaceutical ingredient (API) or Cisatracurium Besylate finished formulations upon request. The Cisatracurium Besylate suppliers may include Cisatracurium Besylate API manufacturers, exporters, distributors and traders.
click here to find a list of Cisatracurium Besylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cisatracurium Besylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Cisatracurium Besylate active pharmaceutical ingredient (API) in detail. Different forms of Cisatracurium Besylate DMFs exist exist since differing nations have different regulations, such as Cisatracurium Besylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cisatracurium Besylate DMF submitted to regulatory agencies in the US is known as a USDMF. Cisatracurium Besylate USDMF includes data on Cisatracurium Besylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cisatracurium Besylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cisatracurium Besylate suppliers with USDMF on PharmaCompass.
A Cisatracurium Besylate CEP of the European Pharmacopoeia monograph is often referred to as a Cisatracurium Besylate Certificate of Suitability (COS). The purpose of a Cisatracurium Besylate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cisatracurium Besylate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cisatracurium Besylate to their clients by showing that a Cisatracurium Besylate CEP has been issued for it. The manufacturer submits a Cisatracurium Besylate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cisatracurium Besylate CEP holder for the record. Additionally, the data presented in the Cisatracurium Besylate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cisatracurium Besylate DMF.
A Cisatracurium Besylate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cisatracurium Besylate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cisatracurium Besylate suppliers with CEP (COS) on PharmaCompass.
A Cisatracurium Besylate written confirmation (Cisatracurium Besylate WC) is an official document issued by a regulatory agency to a Cisatracurium Besylate manufacturer, verifying that the manufacturing facility of a Cisatracurium Besylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cisatracurium Besylate APIs or Cisatracurium Besylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Cisatracurium Besylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Cisatracurium Besylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cisatracurium Besylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cisatracurium Besylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cisatracurium Besylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cisatracurium Besylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cisatracurium Besylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cisatracurium Besylate suppliers with NDC on PharmaCompass.
Cisatracurium Besylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cisatracurium Besylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cisatracurium Besylate GMP manufacturer or Cisatracurium Besylate GMP API supplier for your needs.
A Cisatracurium Besylate CoA (Certificate of Analysis) is a formal document that attests to Cisatracurium Besylate's compliance with Cisatracurium Besylate specifications and serves as a tool for batch-level quality control.
Cisatracurium Besylate CoA mostly includes findings from lab analyses of a specific batch. For each Cisatracurium Besylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cisatracurium Besylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cisatracurium Besylate EP), Cisatracurium Besylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cisatracurium Besylate USP).
